Year All202620252024202320222021 KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion 06-01-2022 KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline 05-15-2022 KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates 05-12-2022 KemPharm to Present at Multiple Upcoming Investor Conferences 05-11-2022 KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH) 05-05-2022 KemPharm to Report First Quarter 2022 Financial Results 05-04-2022 KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX) 04-19-2022 KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates 03-30-2022 KemPharm to Participate in Maxim’s 2022 Virtual Growth Conference 03-24-2022 KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial 03-21-2022
KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion 06-01-2022
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline 05-15-2022
KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH) 05-05-2022
KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX) 04-19-2022
KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates 03-30-2022
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial 03-21-2022
